Study guide
5.1 Validated Questionnaires & Screening Instruments
Certification in Clinical Sleep Health CCSH
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Sleep Physiology
1.1 CCSH Exam Overview & Clinical Scope 1.2 Sleep Architecture, Stages & Normal Cycles 1.3 Neurobiology & The Two-Process Model of Sleep
2 Chapter 2: Circadian Biology, Lifespan & Normal Variation
2.1 Circadian Biology & Melatonin Regulation 2.2 Sleep Across the Lifespan: Pediatric to Geriatric 2.3 Sex, Gender, Environment & Culture: Variations in Normal Sleep
3 Chapter 3: Abnormal Sleep: Classification, Prevalence & Consequences
3.1 Classification, Terminology, Prevalence & Acute vs. Chronic Sleep Disturbances 3.2 Short- and Long-Term Effects of Sleep Disruption, Deprivation & Restriction
4 Chapter 4: Comorbid Medical & Mental Health Conditions
4.1 Cardiopulmonary, Metabolic & Neurological Comorbidities 4.2 Mental Health Disorders, Substance Use & Sleep 4.3 Chronic Pain & Other Medical Conditions Affecting Sleep
5 Chapter 5: Clinical Assessment, Documentation & Medications
5.1 Validated Questionnaires & Screening Instruments 5.2 Comprehensive Sleep History & Physical Assessment 5.3 Quality of Life, Health Changes & Clinical Documentation 5.4 Medications, OTC Products, Supplements & Substances: Effects on Sleep
6 Chapter 6: Sleep Testing & Explaining Results
6.1 Diagnostic Sleep Testing Modalities 6.2 Split-Night and Titration Studies, PAP-NAP, Oximetry & Explaining Results
7 Chapter 7: Sleep-Related Breathing Disorders
7.1 Obstructive Sleep Apnea: Pathophysiology & Diagnosis 7.2 Central Sleep Apnea, Cheyne-Stokes & Emergent Apneas 7.3 Sleep-Related Hypoventilation & Obesity Hypoventilation Syndrome
8 Chapter 8: Positive Airway Pressure Therapy & Titration
8.1 Modes of PAP Therapy: CPAP, APAP, BiPAP & ASV 8.2 Interfaces, Humidification & Equipment Troubleshooting 8.3 Objective PAP Adherence Monitoring & Troubleshooting
9 Chapter 9: Non-PAP Treatments for Sleep Apnea
9.1 Oral Appliance Therapy: Indications, Candidacy & Side Effects 9.2 Surgical Interventions & Hypoglossal Nerve Stimulation 9.3 Positional Therapy & Lifestyle Modifications
10 Chapter 10: Insomnia & Circadian Rhythm Sleep-Wake Disorders
10.1 Chronic Insomnia: ICSD-3 Classification & Assessment 10.2 Cognitive Behavioral Therapy for Insomnia (CBT-I) Principles 10.3 Circadian Rhythm Sleep-Wake Disorders & Light Therapy
11 Chapter 11: Hypersomnias, Parasomnias & Movement Disorders
11.1 Central Disorders of Hypersomnolence 11.2 Parasomnias: NREM & REM Sleep Behavior Disorders 11.3 Sleep-Related Movement Disorders: RLS & PLMD
12 Chapter 12: Patient, Family & Community Education
12.1 Health Literacy, Plain Language & Teach-Back 12.2 Cultural Competency, Diversity of the Learner & Language Access 12.3 Readiness to Learn & Teaching Across Age, Development and Role 12.4 Learning Styles, Adult Learning Principles & Teaching Methods 12.5 Communication Barriers, Disabilities & Educating Families, Professionals and the Community
13 Chapter 13: Self-Management & Behavior Change
13.1 Motivational Interviewing & Overcoming Treatment Barriers 13.2 Sleep Hygiene Education Across Lifestyles and Settings 13.3 Self-Assessment & Self-Management Tools 13.4 Commercial Drivers, Transportation Regulations & Drowsy Driving
14 Chapter 14: Care Coordination, Guidelines, Telehealth & Ethics
14.1 Interdisciplinary Care Coordination & Patient Navigation 14.2 Chronic Disease Model, Care Plans & AASM Clinical Practice Guidelines 14.3 Telehealth Modalities & Remote Patient Monitoring 14.4 Ethics, Scope of Practice & Legal Standards
15 Chapter 15: Program Administration, Public Health & Safety
15.1 Building Collaborative Sleep Programs: Perioperative, Occupational, Outpatient & Support Models 15.2 Quality Improvement, Clinical Outcomes & Accreditation Standards 15.3 Sleep as a Public Health Issue: Community Outreach & Public Policy 15.4 Clinical Safety, Infection Control & Emergency Protocols
5.1 Validated Questionnaires & Screening Instruments
Key Takeaways Explain This Topic AI
The Epworth Sleepiness Scale (ESS) rates the chance of dozing in 8 situations (0–3 each, total 0–24); a total above 10 indicates excessive daytime sleepiness, and 16–24 is severe.
The STOP-Bang questionnaire is an 8-item screening tool exhibiting high sensitivity (>90%) for moderate-to-severe OSA, categorizing patients into low (0-2), intermediate (3-4), or high risk (5-8, or 2+ STOP items plus specific demographic risk factors).
The Berlin Questionnaire stratifies OSA risk into high or low across three symptom categories (snoring/apneas, daytime sleepiness/fatigue, and hypertension/BMI >30 kg/m²), requiring positive findings in at least two categories for high risk.
The Insomnia Severity Index (ISI, clinical cutoff ≥15) and Pittsburgh Sleep Quality Index (PSQI, global cutoff >5) provide validated metrics for quantifying insomnia severity, overall sleep disturbance, and longitudinal treatment response.
The FOSQ-10 scores how sleepiness affects daily function from 5 to 20 (higher is better); 17.9 or higher is commonly treated as normal.
Last updated: October 2026
5.1 Validated Questionnaires & Screening Instruments
Clinical sleep assessment begins with systematic triage using standardized, validated questionnaires. These instruments quantify subjective symptom burdens, stratify patient risk for obstructive sleep apnea (OSA) and insomnia, and establish objective baselines against which therapeutic efficacy can be measured over time. While questionnaires cannot substitute for objective diagnostic sleep testing, their structured implementation optimizes clinical resource allocation, identifies occult sleep pathology in ambulatory and perioperative settings, and reveals discrepancies between subjective patient perceptions and objective physiological parameters.
Epworth Sleepiness Scale (ESS)
Developed by Dr. Murray Johns in 1991, the Epworth Sleepiness Scale (ESS) is the worldwide standard for quantifying subjective daytime sleep propensity. Rather than assessing generalized physical fatigue, lethargy, or tiredness, the ESS specifically measures a patient's likelihood of falling asleep in active and passive everyday situations.
Structure and Administration
The instrument presents eight distinct daily scenarios. Patients rate their likelihood of dozing or nodding off on a 4-point Likert scale (0 to 3) based on their recent life experience:
- 0 = Would never doze
- 1 = Slight chance of dozing
- 2 = Moderate chance of dozing
- 3 = High chance of dozing
The eight standardized situational items are:
- Sitting and reading
- Watching television
- Sitting inactive in a public place (such as a theater, lecture hall, or business meeting)
- As a passenger in a car for an hour without a break
- Lying down to rest in the afternoon when circumstances permit
- Sitting and talking to someone
- Sitting quietly after a lunch without alcohol
- In a car, while stopped for a few minutes in traffic
- Scoring and Clinical Stratification
Individual item scores are summed to generate a cumulative score ranging from 0 to 24 :
- 0 to 5 : Lower normal daytime sleepiness
- 6 to 10 : Higher normal daytime sleepiness
- 11 to 12 : Mild excessive daytime sleepiness (EDS)
- 13 to 15 : Moderate excessive daytime sleepiness
- 16 to 24 : Severe excessive daytime sleepiness
These bands are the ones published by the scale's developer, Dr. Johns.
A total score above 10 is the conventional threshold for excessive daytime sleepiness that warrants further evaluation.
Clinical Interpretation and Limitations
The ESS measures a persistent trait—the general daytime sleep propensity—rather than a fluctuating acute state. However, clinical sleep health specialists must recognize several critical limitations:
Subjective Recall Bias and Habituation : Patients with chronic, longstanding sleep disorders often habituate to daytime somnolence, misinterpreting severe sleepiness as normal aging or occupational stress.
Deliberate Underreporting : Individuals in safety-critical occupations (such as commercial motor vehicle drivers, airline pilots, and heavy equipment operators) frequently underreport symptoms on the ESS to avoid regulatory disqualification or license suspension.
Fatigue vs. Sleepiness Confusion : Patients frequently conflate physical exhaustion, low energy, and depressive apathy with true physiological sleepiness.
Discordance with Objective Metrics : The ESS demonstrates only weak-to-moderate correlation with objective measures of daytime sleep propensity, such as the Multiple Sleep Latency Test (MSLT). A patient with severe sleep-disordered breathing may record an ESS score under 10, while a patient with an elevated ESS may demonstrate normal objective latency on testing.
STOP-Bang Questionnaire
Originally developed and validated by Dr. Frances Chung and colleagues for preoperative anesthesia risk stratification, the STOP-Bang Questionnaire has become the primary screening tool for obstructive sleep apnea across primary care, cardiology, bariatrics, and sleep clinics.
The Eight Dichotomous Components
The questionnaire consists of eight concise, objective Yes/No questions (1 point per affirmative answer, range 0 to 8):
Acronym Clinical Domain Screening Criterion
S Snoring Do you snore loudly (louder than talking or loud enough to be heard through closed doors)?
T Tired Do you often feel tired, fatigued, or sleepy during daytime?
O Observed Has anyone observed you stop breathing, choking, or gasping during your sleep?
P Pressure Do you have or are you being treated for high blood pressure?
B BMI Body Mass Index greater than 35 kg/m² ?
A Age Age older than 50 years ?
N Neck Neck size large: shirt collar 17 inches (43 cm) or larger for men, or 16 inches (41 cm) or larger for women?
G Gender Male gender assigned at birth?
Scoring and Risk Stratification
Patients are stratified into three distinct risk tiers based on cumulative score:
- Low Risk for OSA : Score of 0 to 2
- Intermediate Risk for OSA : Score of 3 to 4
- High Risk for OSA : Score of 5 to 8
Additionally, validated alternative criteria classify a patient as High Risk even with a lower cumulative score if they meet:
- 2 or more STOP items PLUS Male gender ; OR
- 2 or more STOP items PLUS BMI >35 kg/m² ; OR
2 or more STOP items PLUS neck circumference of 17 in or more (male) or 16 in or more (female) .
Diagnostic Performance Profile
The primary clinical strength of STOP-Bang lies in its exceptional sensitivity:
Sensitivity exceeds 90% to 93% for moderate-to-severe OSA (Apnea-Hypopnea Index [AHI] ≥15 events/hour).
Sensitivity approaches 96% to 100% for severe OSA (AHI ≥30 events/hour).
Specificity is modest ( 30% to 45% ), reflecting a trade-off designed to minimize false negatives during clinical triage.
Because of its high negative predictive value (NPV), a score of 0 to 2 reliably rules out moderate-to-severe OSA in general surgical and clinic populations.
Berlin Questionnaire
The Berlin Questionnaire is an epidemiological and clinical screening instrument developed during the 1996 Conference on Sleep in Primary Care in Berlin, Germany. It assesses OSA risk across three distinct categorical symptom domains.
Structure and Scoring Categories
The instrument comprises 10 self-administered questions organized into three clinical categories:
Category 1: Snoring and Witnessed Apneas (5 questions)
Evaluates snoring presence, loudness, frequency, disruptiveness to others, and witnessed breathing cessations.
Positive Score : High-risk responses in 2 or more items within this category.
Category 2: Daytime Sleepiness and Fatigue (4 questions)
Evaluates feeling tired or unrested upon awakening, daytime fatigue/tiredness frequency, and nodding off while driving.
Positive Score : High-risk responses in 2 or more items within this category.
Category 3: Cardiovascular Comorbidity and Obesity (1 question)
Evaluates diagnosed systemic hypertension or a measured Body Mass Index >30 kg/m² .
Positive Score : Presence of hypertension OR a BMI exceeding 30 kg/m².
Risk Classification
High Risk for OSA : Positive scores in 2 or more categories (e.g., Categories 1 and 3, or Categories 1, 2, and 3).
Low Risk for OSA : Positive score in only 1 category or 0 categories .
In primary care settings, the Berlin Questionnaire demonstrates a sensitivity of approximately 86% and a specificity of 77% for predicting an AHI >5, making it a reliable referral filter for general medical practitioners.
Insomnia Severity Index (ISI)
Developed by Dr. Charles Morin, the Insomnia Severity Index (ISI) is a brief, 7-item patient-reported outcome measure evaluating the nature, severity, and daytime impact of insomnia symptoms over the preceding two weeks.
Evaluated Domains and Scoring
Each item is scored on a 5-point Likert scale (0 = none/not at all, to 4 = very severe/very much), yielding a global score of 0 to 28 :
- Severity of sleep onset difficulty (initial insomnia)
- Severity of sleep maintenance difficulty (middle insomnia)
- Severity of early morning awakening problems (terminal insomnia)
- Current satisfaction with sleep pattern
- Noticeability of sleep impairment to others regarding quality of life
- Level of distress or worry caused by current sleep difficulties
- Degree of daytime interference with occupational and social functioning
- Clinical Thresholds and Interpretation
- Global Score Range Clinical Category Clinical Meaning
- 0 to 7 No clinically significant insomnia Normal sleep patterns; absence of clinically relevant pathology
- 8 to 14 Subthreshold insomnia Mild insomnia symptoms; monitor or provide preventative sleep hygiene education
15 to 21 Clinical insomnia (moderate severity) Clinically significant insomnia warranting behavioral therapy or formal clinical evaluation
22 to 28 Clinical insomnia (severe) Severe insomnia associated with profound daytime disability and psychological distress
Longitudinal Tracking in Behavioral Sleep Medicine
The ISI is the most widely used instrument for tracking patient response to Cognitive Behavioral Therapy for Insomnia (CBT-I) and pharmacotherapy. Clinical significance benchmarks include:
Clinically Meaningful Improvement : A reduction of ≥6 points from baseline.
Clinical Remission : Achieving a post-treatment score of ≤7 points .
Pittsburgh Sleep Quality Index (PSQI)
Developed in 1989 by Dr. Daniel Buysse and colleagues at the University of Pittsburgh, the Pittsburgh Sleep Quality Index (PSQI) evaluates broad, multi-dimensional sleep quality and sleep disturbances over a 1-month recall window .
Instrument Architecture
The questionnaire includes 19 self-administered questions (and 5 optional bed partner/roommate questions used for qualitative clinical insight). The 19 items combine to form 7 clinical component scores , each rated from 0 (no difficulty) to 3 (severe difficulty):
- Subjective sleep quality (overall self-rating)
- Sleep latency (minutes to fall asleep and frequency of taking >30 minutes)
- Sleep duration (hours of actual nocturnal sleep achieved)
- Habitual sleep efficiency (ratio of total sleep time to time in bed)
- Sleep disturbances (nocturnal awakenings, coughing, nocturia, pain, temperature)
- Use of sleep medications (prescription and over-the-counter sleep aids)
- Daytime dysfunction (trouble staying awake and maintaining enthusiasm)
- Global Scoring and Diagnostic Cutoff
The seven component scores are summed to generate a Global PSQI Score ranging from 0 to 21 :
- Global Score ≤5 : Good sleep quality
- Global Score >5 : Poor sleep quality
A global score cutoff >5 demonstrates a sensitivity of 89.6% and a specificity of 86.5% in distinguishing good sleepers from poor sleepers with clinical sleep disorders.
Functional Outcomes of Sleep Questionnaire (FOSQ)
The blueprint names the Functional Outcomes of Sleep Questionnaire (FOSQ) among the tools a CCSH must administer and interpret. Developed by Terri Weaver and colleagues in 1997, the FOSQ measures how sleepiness affects everyday functioning, not just how likely a person is to doze.
Structure
FOSQ-30: the original 30-item version with five subscales: Activity Level, Vigilance, Intimacy and Sexual Relationships, General Productivity, and Social Outcome .
FOSQ-10: a 10-item short form (Chasens and colleagues, 2009) that keeps the same five subscales and tracks the full version closely; it is the version most clinics use.
Each item asks whether the person has difficulty with an activity because they are sleepy or tired , rated from 1 (extreme difficulty) to 4 (no difficulty), with an option for "I don't do this activity for other reasons."
Scoring and Interpretation
Subscale scores combine into a total score from 5 to 20 . Higher scores mean better functioning.
A total of 17.9 or higher is commonly used as the threshold for normal functioning, based on Weaver's normative work.
A change of about 2 points is generally treated as clinically meaningful.
Clinical Use
The FOSQ captures outcomes patients care about, such as staying alert while driving, getting work done and intimacy. It improves with effective treatment, so programs report it alongside PAP adherence data to show benefit. Its direction is the opposite of the ESS: a rising FOSQ is good, while a rising ESS is bad. Read score changes carefully before documenting them.
Tip
The sleep diary is also a named blueprint tool. The sleep history section shows how to calculate time in bed, total sleep time and sleep efficiency from a two-week diary.
Comprehensive Questionnaire Comparison Table
Screening Tool Primary Target Domain Number of Items & Scoring Range Validated Diagnostic Cutoff Sensitivity / Specificity Profile Clinical Utility & Limitations
Epworth Sleepiness Scale (ESS) Subjective daytime sleep propensity across daily life situations 8 items; scored 0–3 per item (Total: 0–24) Score >10 indicates Excessive Daytime Sleepiness (EDS) Modest sensitivity; low-to-moderate correlation with objective MSLT Excellent triage tool; vulnerable to subjective underreporting and habituation bias
STOP-Bang Preoperative and ambulatory screening for OSA risk 8 dichotomous items; scored 0 or 1 (Total: 0–8) 0–2 : Low Risk; 3–4 : Intermediate Risk; 5–8 : High Risk (or 2+ STOP + risk factor) Sensitivity >90% for moderate-to-severe OSA; specificity 30–45% Outstanding triage sensitivity and negative predictive value; high false-positive rate due to low specificity
Berlin Questionnaire Primary care identification of obstructive sleep apnea risk 10 items grouped into 3 distinct categories Positive score in ≥2 of 3 categories defines High Risk Sensitivity ~86%, specificity ~77% in ambulatory populations Well-validated in primary care; categorizes risk rather than providing numerical severity score
Insomnia Severity Index (ISI) Subjective insomnia severity, daytime impact, and distress 7 items; scored 0–4 per item (Total: 0–28) ≥15 : Moderate clinical insomnia; ≥22 : Severe clinical insomnia; ≤7 : Remission A score of about 10–11 or higher best detected insomnia in validation studies Gold standard for evaluating CBT-I outcomes; clinically meaningful response is ≥6-point decrease
Pittsburgh Sleep Quality Index (PSQI) Multi-dimensional sleep quality and disturbance over past month 19 self-rated items; 7 component scores (Total: 0–21) Global Score >5 indicates poor sleep quality Sensitivity 89.6%, specificity 86.5% for poor sleep quality Comprehensive global measure; 1-month recall window limits utility for acute night-to-night tracking
Functional Outcomes of Sleep Questionnaire (FOSQ-10) Effect of sleepiness on daily functioning 10 items in 5 subscales (Total: 5–20) Total ≥17.9 treated as normal functioning Responsive to treatment; about 2 points is a meaningful change Higher is better (opposite of ESS); measures function, not dozing